Marksans Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2025.
The company has reported 13.94% rise in its net profit at Rs 37.59 crore for the quarter under review as compared to Rs 32.99 crore for the same quarter in the previous year. The total income of the company increased by 29.39% at Rs 307.17 crore for Q4FY25 as compared to Rs 237.39 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 16.86% rise in its net profit at Rs 90.73 crore for fourth quarter ended March 31, 2025 as compared to Rs 77.64 crore for the same quarter in the previous year. The total income of the company increased by 25.75% at Rs 724.98 crore for Q4FY25 as compared to Rs 576.54 crore for the corresponding quarter previous year.
For the year ended March 31, 2025, the company has reported 40.75% rise in its net profit at Rs 188.27 crore as compared to Rs 133.76 crore for the previous year. The total income of the company increased by 35.93% at Rs 1,244.21 crore for year under review as compared to Rs 915.35 crore for year ended March 31, 2024.
For the year ended March 31, 2025, on the consolidated basis, the company has reported 21.51% rise in its net profit at Rs 382.62 crore as compared to Rs 314.90 crore for the previous year. The total income of the company increased by 20.89% at Rs 2,693.22 crore for year under review as compared to Rs 2,227.83 crore for year ended March 31, 2024.
